295 related articles for article (PubMed ID: 34333454)
1. Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas.
Aoki K; Suzuki H; Yamamoto T; Yamamoto KN; Maeda S; Okuno Y; Ranjit M; Motomura K; Ohka F; Tanahashi K; Hirano M; Nishikawa T; Shimizu H; Kitano Y; Yamaguchi J; Yamazaki S; Nakamura H; Takahashi M; Narita Y; Nakada M; Deguchi S; Mizoguchi M; Momii Y; Muragaki Y; Abe T; Akimoto J; Wakabayashi T; Saito R; Ogawa S; Haeno H; Natsume A
Cancer Res; 2021 Sep; 81(18):4861-4873. PubMed ID: 34333454
[TBL] [Abstract][Full Text] [Related]
2. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
[TBL] [Abstract][Full Text] [Related]
3. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
4. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
[TBL] [Abstract][Full Text] [Related]
5. Malignant Transformation of Molecularly Classified Adult Low-Grade Glioma.
Tom MC; Park DYJ; Yang K; Leyrer CM; Wei W; Jia X; Varra V; Yu JS; Chao ST; Balagamwala EH; Suh JH; Vogelbaum MA; Barnett GH; Prayson RA; Stevens GHJ; Peereboom DM; Ahluwalia MS; Murphy ES
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1106-1112. PubMed ID: 31461674
[TBL] [Abstract][Full Text] [Related]
6. Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?
Franceschi E; Tosoni A; De Biase D; Lamberti G; Danieli D; Pizzolitto S; Zunarelli E; Visani M; Di Oto E; Mura A; Minichillo S; Scafati C; Asioli S; Paccapelo A; Bartolini S; Brandes AA
Oncologist; 2019 May; 24(5):664-670. PubMed ID: 30777895
[TBL] [Abstract][Full Text] [Related]
7. Conventional MR-based Preoperative Nomograms for Prediction of IDH/1p19q Subtype in Low-Grade Glioma.
Liu Z; Zhang T; Jiang H; Xu W; Zhang J
Acad Radiol; 2019 Aug; 26(8):1062-1070. PubMed ID: 30393056
[TBL] [Abstract][Full Text] [Related]
8. Radiogenomic association between the T2-FLAIR mismatch sign and IDH mutation status in adult patients with lower-grade gliomas: an updated systematic review and meta-analysis.
Han Z; Chen Q; Zhang L; Mo X; You J; Chen L; Fang J; Wang F; Jin Z; Zhang S; Zhang B
Eur Radiol; 2022 Aug; 32(8):5339-5352. PubMed ID: 35169897
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy delays malignant transformation and prolongs survival in patients with IDH-mutant gliomas.
Liu Y; Chen H; Li G; Zhang J; Yao K; Wu C; Li S; Qiu X
Cancer Biol Med; 2022 Nov; 19(10):1477-86. PubMed ID: 36350001
[TBL] [Abstract][Full Text] [Related]
10. Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas.
Al-Ali R; Bauer K; Park JW; Al Abdulla R; Fermi V; von Deimling A; Herold-Mende C; Mallm JP; Herrmann C; Wick W; Turcan Ş
Acta Neuropathol Commun; 2019 Dec; 7(1):201. PubMed ID: 31806013
[TBL] [Abstract][Full Text] [Related]
11. Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas.
Yamauchi T; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Kitagawa Y; Kondo E; Tsushita N; Satomi K; Yoshida A; Ichimura K; Narita Y
Brain Tumor Pathol; 2018 Jul; 35(3):148-158. PubMed ID: 29922974
[TBL] [Abstract][Full Text] [Related]
12. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma.
Chai RC; Zhang KN; Chang YZ; Wu F; Liu YQ; Zhao Z; Wang KY; Chang YH; Jiang T; Wang YZ
Carcinogenesis; 2019 Oct; 40(10):1229-1239. PubMed ID: 31157866
[TBL] [Abstract][Full Text] [Related]
13. Combining hyperintense FLAIR rim and radiological features in identifying IDH mutant 1p/19q non-codeleted lower-grade glioma.
Li M; Ren X; Chen X; Wang J; Shen S; Jiang H; Yang C; Zhao X; Zhu Q; Cui Y; Lin S
Eur Radiol; 2022 Jun; 32(6):3869-3879. PubMed ID: 35079884
[TBL] [Abstract][Full Text] [Related]
14. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
15. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
[TBL] [Abstract][Full Text] [Related]
16. IDH mutation is associated with higher risk of malignant transformation in low-grade glioma.
Leu S; von Felten S; Frank S; Boulay JL; Mariani L
J Neurooncol; 2016 Apr; 127(2):363-72. PubMed ID: 26780338
[TBL] [Abstract][Full Text] [Related]
17. Conventional MRI features can predict the molecular subtype of adult grade 2-3 intracranial diffuse gliomas.
Lasocki A; Buckland ME; Drummond KJ; Wei H; Xie J; Christie M; Neal A; Gaillard F
Neuroradiology; 2022 Dec; 64(12):2295-2305. PubMed ID: 35606654
[TBL] [Abstract][Full Text] [Related]
18. Automated apparent diffusion coefficient analysis for genotype prediction in lower grade glioma: association with the T2-FLAIR mismatch sign.
Aliotta E; Dutta SW; Feng X; Tustison NJ; Batchala PP; Schiff D; Lopes MB; Jain R; Druzgal TJ; Mukherjee S; Patel SH
J Neurooncol; 2020 Sep; 149(2):325-335. PubMed ID: 32909115
[TBL] [Abstract][Full Text] [Related]
19. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
[TBL] [Abstract][Full Text] [Related]
20. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
